[{"data":1,"prerenderedAt":133},["ShallowReactive",2],{"drug-flutamide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":53,"warnings":63,"renal":71,"monitoring":72,"interactions":73,"review":74,"examples":77,"atc":83,"iran":85,"usApproval":101,"links":107,"populations":123},"flutamide",1,{"fa":7,"en":8},"فلوتامید","Flutamide","antineoplastic-immunomodulating",{"fa":11,"en":12},"ضدآندروژن غیراستروئیدی","Non-steroidal antiandrogen",[14],{"name":15,"market":16},"Eulexin","US",[18,19,7],"eulexin","اولکسین",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"cap-125","capsule","oral","125 mg capsule",{"amount":27,"unit":28,"perUnit":23,"scored":29},125,"mg",false,[16],[32],{"source":33,"section":34},"fda-eulexin","Description",[36],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":50},"prostate","prostate-cancer",{"fa":40,"en":41},"سرطان پروستات مرحله B2-C و D2 (با آگونیست LHRH) — ۲۵۰ mg (۲ کپسول) سه بار در روز هر ۸ ساعت","Stage B2-C and D2 prostate cancer (with LHRH agonist) — 250 mg (2 capsules) three times daily every 8 h",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":48,"dosesPerDay":49},250,3,[51],{"source":33,"section":52},"Dosage and Administration",[54],{"id":55,"severity":56,"text":57,"refs":60},"ci","block",{"fa":58,"en":59},"حساسیت به فلوتامید؛ نارسایی شدید کبد (آنزیم‌های کبد پیش از شروع).","Hypersensitivity to flutamide; severe hepatic impairment (check liver enzymes before starting).",[61],{"source":33,"section":62},"Contraindications",[64],{"text":65,"refs":68},{"fa":66,"en":67},"آسیب کبدی — بستری و به‌ندرت مرگ از نارسایی کبد؛ آنزیم کبد پایه، ماهانه ۴ ماه و سپس دوره‌ای.","Hepatic injury — hospitalisation and rarely death from liver failure; baseline liver enzymes, monthly for 4 months, then periodically.",[69],{"source":33,"section":70},"Warnings",[],[],[],{"status":75,"reviewer":76,"date":76},"unverified",null,[78],{"regimen":37,"formulation":22,"input":79,"expect":81},{"ageYears":80,"weightKg":80},70,{"perDose":48,"tabletsPerDoseRounded":82},2,[84],"L02BB01",{"status":86,"forms":87,"refs":96},"registered",[88,92],{"code":89,"en":90,"fa":91},"21780","EULEXIN250MG  TAB","قرص اولکسین ۲۵۰ میلی‌گرم",{"code":93,"en":94,"fa":95},"00560","FLUTAMIDE 250MG TAB","قرص فلوتامید ۲۵۰ میلی‌گرم",[97],{"source":98,"section":99,"url":100},"darooyab-generic","G-1004\u002FFlutamide","https:\u002F\u002Fwww.darooyab.ir\u002FG-1004\u002FFlutamide",{"kind":102,"refs":103,"id":106},"ANDA",[104],{"source":33,"section":105},"SPL approval \u002F marketing category","ANDA075298",[108,111,115,118,121],{"kind":109,"url":110,"label":106},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=075298",{"kind":112,"url":113,"label":114},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=0a905e25-42b6-4937-a689-f01a8f22e644","FDA Eulexin",{"kind":116,"url":117,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa697045.html",{"kind":119,"url":120,"label":84},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L02BB01",{"kind":122,"url":100,"label":8},"darooyab",{"pregnancy":124},{"level":125,"text":126,"quote":129,"refs":130},"avoid",{"fa":127,"en":128},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Pregnancy Category D There was decreased 24 hour survival in the offspring of pregnant rats treated with Eulexin ® at doses of 30, 100 or 200 mg\u002Fkg\u002Fday (approximately 3, 9 and 19 times the human dose).",[131],{"source":33,"section":132},"Pregnancy",1792444399781]